1888 PressRelease Home	Sign In	Register	About Us	Sitemap

1888 Press Release | Anavex Life Sciences Corp. Press Releases

Anavex.com - Anavex Life Sciences Corp. Company News Section

Anavex Life Sciences Corp. Information

Nick Boutsalis

URL: http://www.anavex.com

Anavex Life Sciences Corp. (www.anavex.com) is an emerging biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases such as Alzheimer's, epilepsy and depression. The company's proprietary SIGMACEPTOR(tm) Discovery Platform involves the rational design of drug compounds that fulfill specific criteria based on unmet market needs and new scientific advances.

Anavex Life Sciences Corp. Press Release -

Anavex.com

01 OCT	ANAVEX contracts FORENAP Pharma for clinical trials of ANAVEX 2-73 in Alzheimer’'s disease
	Anavex Life Sciences Corp. has selected FORENAP Pharma EURL as the contract research organization (CRO).

22 SEP	ANAVEX completes scale-up manufacturing of ANAVEX 2-73 for Phase I Alzheimer's disease clinical trials
	Anavex Life Sciences Corp. today announced the completion of scale-up manufacturing of ANAVEX 2-73, its lead compound for the treatment of Alzheimer’s disease.

17 JUN	ANAVEX appoints Dr. Hervede Kergrohen as CEO to lead company through clinical trials and future growth
	Anavex Life Sciences Corp., (OTCBB: AVXL) today announced the immediate appointment of Hervé de Kergrohen, MD, MBA, as its Chief Executive Officer (CEO) and director.

10 APR	Pharmawire: Medivation, Anavex May Lower Oxidative Stress
	Anavex Life Sciences (OTCBB: AVXL) was highlighted in a feature story published by Pharmawire on March 31, 2009.

11 FEB	Anavex Appoints Leading Alzheimer's Disease Expert Dr. Mark Smith To Scientific Advisory Board
	Anavex Life Sciences Corp. (OTCBB: AVXL) today announced the appointment of Dr. Mark A. Smith.

18 DEC	Ground-breaking anti-amnesic and neuroprotective effects of Alzheimer's compound ANAVEX 1-41 published in Journal of Neuropsychopharmacology
	Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) announces that the anti-amnesic and neuroprotective effects of ANAVEX 1-41 are detailed in a paper published in the current edition of Neuropsychopharmacology.

08 DEC	Anavex presents potent neuroprotective effects of Anavex 1-41 at Neuroscience 2008
	Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) was selected to present its latest results with ANAVEX 1-41 at Neuroscience 2008, the 38th annual meeting of the Society for Neuroscience, which took place November 15-19, 2008 in Washington, DC.

06 SEP	Anavex Completes Successful Preclinical Studies On Lead Alzheimer's Drug Candidate
	Anavex completes successful preclinical studies on ANAVEX 2-73, a novel sigma-1 receptor agonist for the treatment of Alzheimer's disease.